S
oft tissue sarcomas are a heterogenous group of more than 70 cancers of connective tissue that share enough characteristics to be lumped together for analysis. Despite certain similarities, differences exist in tumor biology and response to specific therapies between the histological subtypes. Surgery is the mainstay of treatment of these cancers, but is associated with high rates of local recurrence and morbidity. Patients who incur local recurrence of their sarcoma have a higher rate of metastases, but a causative relationship has not been proven [1] . Nevertheless, surgeons and patients want to avoid local recurrence and its local consequences.
Local long-term control of disease can be enhanced by adding radiation therapy before or after surgery, and radiotherapy is appropriate in most patients with high-grade soft tissue sarcomas [3, 14] . In certain situations and locations, radiation can be avoided, such as after radical compartmental resection [2, 12] .
Although radiotherapy is an effective adjuvant used in various forms or sequences to reduce the rate of local recurrence, no difference has been detected in terms of the overall likelihood of cure, and some clinicians question its value [1] . To complicate matters, even the dogma that local recurrence does not translate into distant metastasis and death remains controversial. For example, data from the SEER database suggest that there may be a slight survival advantage in patients who received radiation therapy and have lower rates of local recurrence [2] . Despite the ongoing discussion, I believe (and a practice guideline suggests [17] ) that radiotherapy can enhance control of the cancer and functional preservation from surgery.
A cautionary note regarding radiotherapy is its local toxicity that can produce various long-term complications individually or in concert, including fibrosis, ankylosis, edema, weakness, osteonecrosis, fracture, neuropathy, and even radiation sarcoma. Advocates for radiation therapy contend that modern treatment methods avoid most of this toxicity.
I also note that the benefits of radiotherapy can be provided using widely available methods; though there may be benefits to the specialized approach reported by Klein and colleagues [9] In order to determine which therapeutic approach to recommend to which patients, clinicians need to better describe patients' clinical characteristics and surgeon decision-making. This is critical in the multidisciplinary treatment era. Future studies should pay particular attention to patient selection and treatment indications; for us to make progress in this regard, we need to know who received which treatment, and why. While this is possible in retrospective research, it is more likely to occur in the setting of prospective studies with clear inclusion and exclusion criteria, and our specialty needs to focus more on performing studies of this kind. An algorithm can be an effective tool in this regard, but it is only as powerful as the clinicians' discipline in inputting the data and applying it. Other methods such as Bayesian probabilistic analysis may prove to be more powerful [4] .
We need evidence-based evaluations to identify the best method of adjuvant radiotherapy. We still don't know which patient and histologic subtypes are best helped by radiation, nor which mode of radiation therapy is best [14] . The proliferation of new radiotherapy technologies makes it difficult to decide.
Comparative outcome studies between methods ranging from threedimensional planning, cyberknife, brachytherapy, proton beam therapy, and intensity-modulated radiation therapy are strikingly absent. This void persists because institutional biases, the need to amortize the high costs of radiotherapy equipment, and training deficits, among other factors. While Klein and colleagues [9] show encouraging results, and seem to meet their goals of achieving "good function, local control, and low morbidity in patients with extremity soft tissue sarcoma," it is not clear how to use their algorithm in institutions where other techniques are in use, and future studies need to compare a wider variety of contemporary approaches and radiation techniques. It seems likely to me that this will need to be done in a multicenter study. By nature, the single-institution approaches lack generalizability; we have a glaring need for comparative trials of the new technology and techniques. Only then can an algorithm such as the one described by the study authors [9] be tested fully and fairly. The difficulties in performing such studies are daunting due to the parochial nature of treatment strategies, the multidisciplinary nature of care, and the long-term evolution of some of the radiation associated complications. If we can overcome these obstacles, we can tailor therapy to improve local care and functional results of sarcoma care.
Essentially, a better approach for soft tissue sarcoma requires improving each available modality, including chemotherapy, and integrating them more effectively. Systemic therapy is desirable for patients with (or at high risk for developing) metastases [5] . Should future studies use concomitant or sequential chemotherapy among their patient cohort with very large, deep, high grade sarcomas? In addition to the possible systemic benefits of chemotherapy, there seems to be a local benefit that could alter how local recurrence results are interpreted and decisions made. The benefits of chemotherapy and radiotherapy interactions on local control have been studied and summarized in important meta-analyses. While there was a 25% reduction in relative risk for cancer relapse and a 4% absolute reduction in the risk of death at 10 years, there was also a 7% reduction in local recurrence rates for doxorubicin-and ifosfamidebased regimens [10, 13] .
The menu of drugs available for patients with soft tissue sarcomas is burgeoning. New agents and modern therapeutic strategies support tailoring treatment to the histologic subtype and using chemotherapy selectively [6] . It has not been studied how these regimens may also apply to enhance local control of sarcomas with radiation and surgery. Deconstructing the benefits and limitations of one form of therapy (radiation in this case) is a start, but it must then be reconstructed in a multifactorial fashion-with chemotherapy as an important variable.
How Do We Get There?
Cancer itself shows us what must be done to make progress toward our goal of improved sarcoma care. By improving the local and systemic control of our disease, we will build the foundation needed to address clinical questions. Then we can codify our multidisciplinary approach to soft tissue sarcoma and create useful algorithms.
In each of our centers, we need to develop algorithms and refine them. It is no longer acceptable to have such wide variations in treatment. This starts by promoting tighter management of our weekly or monthly tumor boards and record keeping. For example, if a patient is not treated according to the applicable algorithm, we must identify and record the reason(s) why. This simple process will narrow the variation and likely improve clinical care. The most powerful weapon we may have is our data [7] .
Systemically, we can collaborate more. Orthopaedic oncologists may not directly control the method of radiotherapy administration, or what drug protocol is under investigation, but we do have influence because of the clinical authority granted us by the patients. We need to participate in protocol development at every level: Locally, in cooperative groups such as the Radiation Therapy Oncology Group, and Sarcoma Alliance for Research Through Collaboration, and in the pharmaceutical industry. We need to urge our patients to participate in appropriate and available clinical trials; participation enhances our credibility as meaningful collaborators.
The original mission of the Musculoskeletal Tumor Society specified that the organization would work together on important collaborative studies. After some early success in this regard, the organization has not been effective recently in achieving this goal. Nevertheless, success of this collaborative approach can effectively alter practice. For example, in Japan, collaboration of surgeons contributing their data to generate appropriate guidelines defining surgical margin adequacy has changed oncology there [9] , and collaboration has spawned an impressive series of papers documenting the status of care for many of the country's important and rare sarcomas [15, 16] . In a different realm, The Sacropelvic Tumor Study Group (Memorial Sloan Kettering, Massachusetts General Hospital, Mayo Clinic, University of Toronto, and MD Anderson) has shared data regarding the treatment, complications, and outcome of patients with chordoma [11] . Through this mechanism, we have quantified the complications related to radiotherapy, defined clinical outcome, and are negotiating a prospective trial of radiotherapy and surgery. It has taken 6 years to successfully launch this planning stage, but a similar mechanism, if applied to soft tissue sarcoma, would have great potential to yield important data.
